FDA hands down partial clinical hold to Innate Pharma for cancer drug trials after patient death
The FDA has imposed a partial clinical hold on Innate Pharma’s IND for its cancer drug lacutamab, leading to a pause …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
